Overview

This trial is active, not recruiting.

Conditions septic shock, sepsis
Sponsor Universitätsklinikum Hamburg-Eppendorf
Start date February 2012
End date March 2013
Trial size 120 participants
Trial identifier NCT01632059, ADSeS (PV3927)

Summary

Examination of ADMA (Asymmetric-Dimethylarginine)-serum level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in patients with severe Sepsis and septic shock as prognostic value.

This study looks into ADMA as a good prognostic factor for sepsis. Further more the dependency of the ADMA level to the DDAH II polymorphisms is reviewed this study.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
inclusion criteria are severe sepsis and septical shock and must be > 18 y/o

Primary Outcomes

Measure
ADMA serum levels
time frame: 7 days

Secondary Outcomes

Measure
28 day mortality
time frame: 28 day
hospitalisation (ICU and peripheral)
time frame: 28 days
severity of illness
time frame: 28 days
DDAH Ii polymorphism
time frame: 28 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - >18 y/o - sepsis - septical shock Exclusion Criteria: - primary cardiogenic shock - pregnancy - breastfeeding - non compliance - moribund status

Additional Information

Official title Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value
Description Secondary targets are the mortality (28 days ICU), the length of hospitalisation in ICU and peripheral station, the severity of the illness (SAPS II score), the SOFA-score values in the progress and the procalcitonin values in the progress
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf.